Bicara Therapeutics, Inc. (BCAX)
20.56
+0.46
(+2.29%)
USD |
NASDAQ |
Jun 09, 16:00
20.55
-0.01
(-0.05%)
After-Hours: 20:00
Bicara Therapeutics SG&A Expense (Quarterly) : 12.74M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Bridgebio Oncology Therapeutics, Inc. | 6.377M |
| Arrowhead Pharmaceuticals, Inc. | 41.74M |
| Oncolytics Biotech, Inc. | 4.729M |
| Sangamo Therapeutics, Inc. | 6.818M |
| Sarepta Therapeutics, Inc. | 108.95M |